Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?

Breast cancer research and treatment - 1 Jan 2017

Kotsopoulos Joanne, Singer Christian, Narod Steven A

Abstract excerpt

BRCA1 mutation carriers face a high lifetime risk of breast cancer, estimated at 60 % compared to 10 % in the general population. BRCA1 breast cancers typically have an aggressive course (i.e., high-grade, triple-negative) and are associated with a poor prognosis. At present, primary prevention is limited to prophylactic removal of the unaffected breasts. Effective chemopreventive strategies are not yet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Cell Transformation, Neoplastic
Share to Chemoprevention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Osteoprotegerin

Share to Progesterone

Share to RANK Ligand

Share to Receptor Activator of Nuclear Factor-kappa B

Source

Identifiers

PMID: 27783278
DOI: 10.1007/s10549-016-4029-z

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?PMID 27783278Read ↗

RANKL/RANK: from bone loss to the prevention of breast cancer.Semantic proximity Read ↗

RANKL/RANK control Brca1 mutation- .Semantic proximity Read ↗

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.Semantic proximity Read ↗

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Prevention of breast cancer by RANKL/RANK blockade.Semantic proximity Read ↗

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.Semantic proximity Read ↗

RANKL and RANK: From Mammalian Physiology to Cancer Treatment.Semantic proximity Read ↗

RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.Semantic proximity Read ↗

NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer.Semantic proximity Read ↗

The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.Semantic proximity Read ↗

Out-RANKing BRCA1 in Mutation Carriers.Semantic proximity Read ↗

RANKL and RANK in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.